7-44149772-C-T

Variant names:

Variant summary

Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong

The NM_000162.5(GCK):c.667G>A(p.Gly223Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,720 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).

Frequency

Genomes: not found (cov: 33)

Exomes 𝑓: 6.8e-7 ( 0 hom. )

Consequence

GCK
NM_000162.5 missense

Scores

Clinical Significance

Pathogenic criteria provided, multiple submitters, no conflicts P:9

Conservation

PhyloP100: 7.91

Variant links:

Genes affected

GCK (HGNC:4195): (glucokinase) This gene encodes a member of the hexokinase family of proteins. Hexokinases phosphorylate glucose to produce glucose-6-phosphate, the first step in most glucose metabolism pathways. In contrast to other forms of hexokinase, this enzyme is not inhibited by its product glucose-6-phosphate but remains active while glucose is abundant. The use of multiple promoters and alternative splicing of this gene result in distinct protein isoforms that exhibit tissue-specific expression in the pancreas and liver. In the pancreas, this enzyme plays a role in glucose-stimulated insulin secretion, while in the liver, this enzyme is important in glucose uptake and conversion to glycogen. Mutations in this gene that alter enzyme activity have been associated with multiple types of diabetes and hyperinsulinemic hypoglycemia. [provided by RefSeq, Aug 2017]

GCK links:

LOC105375258 (HGNC:):

LOC105375258 links:

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Pathogenic. Variant got 16 ACMG points.

PM1

In a strand (size 17) in uniprot entity HXK4_HUMAN there are 11 pathogenic changes around while only 0 benign (100%) in NM_000162.5

PM2

Very rare variant in population databases, with high coverage;

PP3

MetaRNN computational evidence supports a deleterious effect, 0.991

PP5

Variant 7-44149772-C-T is Pathogenic according to our data. Variant chr7-44149772-C-T is described in ClinVar as [Pathogenic]. Clinvar id is 435306.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
GCK	NM_000162.5 link	c.667G>A	p.Gly223Ser	missense_variant	Exon 6 of 10	ENST00000403799.8	NP_000153.1	P35557-1Q53Y25

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
GCK	ENST00000403799.8 link	c.667G>A	p.Gly223Ser	missense_variant	Exon 6 of 10	1	NM_000162.5	ENSP00000384247.3		P35557-1

Frequencies

GnomAD3 genomes

Cov.:

GnomAD4 exome

AF:

6.84e-7

AC:

AN:

1461720

Hom.:

Cov.:

AF XY:

0.00000138

AC XY:

AN XY:

727162

show subpopulations

Gnomad4 AFR exome

AF:

0.00

Gnomad4 AMR exome

AF:

0.00

Gnomad4 ASJ exome

AF:

0.00

Gnomad4 EAS exome

AF:

0.00

Gnomad4 SAS exome

AF:

0.00

Gnomad4 FIN exome

AF:

0.00

Gnomad4 NFE exome

AF:

8.99e-7

Gnomad4 OTH exome

AF:

0.00

GnomAD4 genome

Cov.:

ClinVar

Significance: Pathogenic

Submissions summary: Pathogenic:9

Revision: criteria provided, multiple submitters, no conflicts

LINK: link

Submissions by phenotype

not provided

Pathogenic:3

Aug 24, 2023

Athena Diagnostics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant segregates with disease in multiple families with clinical features of MODY (PMID: 21437567, 22291974, 22493702) and was also identified in one individual with PNDM (PMID: 26123671). This variant has not been reported in large, multi-ethnic general populations (http://gnomad.broadinstitute.org). Assessment of experimental evidence suggests this variant results in abnormal protein function. Studies show this variant reduces glucokinase activity (PMID: 22291974, 22493702). -

Aug 04, 2022

GeneDx

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Published functional studies demonstrate kinetic inactivation with a decreased rate of catalysis and reduced affinity for glucose (Garca-Herrero et al., 2012; Valentnov et al., 2012); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Missense variants in this gene are often considered pathogenic (HGMD); This variant is associated with the following publications: (PMID: 22291974, 17573900, 16965331, 30663027, 31216263, 33294763, 33565752, 32041611, 28726111, 34789499, Mustafa_2019[Article], 34746319, 26123671, 22493702, 21437567, 11508276) -

Dec 17, 2024

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 223 of the GCK protein (p.Gly223Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with autosomal dominant GCK-related conditions (PMID: 21437567, 31216263, 32041611, 33294763, 33565752). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 435306). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt GCK protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects GCK function (PMID: 22291974, 22493702). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. -

Maturity onset diabetes mellitus in young

Pathogenic:2

Feb 21, 2024

Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The p.Gly222Ser variant in GCK has been reported in the heterozygous state in at least 7 individuals with MODY and segregated with disease in 10 affected individuals from 1 family (Valentinova 2012 PMID 22493702, Capuano 2012 PMID 22761713, Delvecchio 2014 PMID 25414397, Antosik 2016 PMID 26123671, Aloi 2017 PMID 28726111, Scully 2020 PMID 33294763). It was also identified in 1/1111930 European chromosomes by gnomAD (http://gnomad.broadinstitute.org, v4.0). This variant has also been reported in ClinVar (Variation ID 435306). In vitro functional studies, computational prediction tools, and conservation analyses support that this variant may impact the protein (Valentinova 2012 PMID 22493702). In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant MODY. ACMG/AMP Criteria Applied: PS4, PP1_Strong, PM2_Supporting, PP3, PS3_Supporting. -

May 17, 2017

Ambry Genetics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The p.G223S pathogenic mutation (also known as c.667G>A), located in coding exon 6 of the GCK gene, results from a G to A substitution at nucleotide position 667. The glycine at codon 223 is replaced by serine, an amino acid with similar properties. This mutation has been identified in numerous individuals ith maturity-onset diabetes of the young, segregating with disease (Osbak KK et al. Hum. Mutat., 2009 Nov;30:1512-26; Borowiec M et al. Acta Diabetol, 2011 Sep;48:203-8; García-Herrero CM et al. PLoS ONE, 2012 Jan;7:e30518; Valentínová L et al. PLoS ONE, 2012 Apr;7:e34541; Capuano M et al. PLoS ONE, 2012 Jun;7:e38906). This mutation was also identified in a compound heterozygous infant with persistent neonatal diabetes (Borowiec M et al. Acta Diabetol, 2011 Sep;48:203-8; Antosik K et al. Acta Diabetol, 2016 Apr;53:337-8). In addition, a GST fusion protein with this alteration expressed in E. coli demonstrated activity levels <10% of wild type with altered kinetics (García-Herrero CM et al. PLoS ONE, 2012 Jan;7:e30518). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -

Type 2 diabetes mellitus;C0342277:Maturity-onset diabetes of the young type 2;C1833104:Permanent neonatal diabetes mellitus;C1865290:Hyperinsulinism due to glucokinase deficiency

Pathogenic:1

Oct 31, 2018

Fulgent Genetics, Fulgent Genetics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Maturity-onset diabetes of the young type 2

Pathogenic:1

Aug 31, 2016

Genetic Services Laboratory, University of Chicago

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

GCK-related disorder

Pathogenic:1

Apr 18, 2024

PreventionGenetics, part of Exact Sciences

Significance: Pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

The GCK c.667G>A variant is predicted to result in the amino acid substitution p.Gly223Ser. This variant has been reported to be causative for maturity onset diabetes of the young (MODY) due to impaired kinetic characteristics of glucokinase (Borowiec et al. 2011. PubMed ID: 21437567; García-Herrero et al. 2012. PubMed ID: 22291974). This variant has not been reported in a large population database, indicating this variant is rare. This variant is interpreted as pathogenic. -

Monogenic diabetes

Pathogenic:1

Oct 27, 2023

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Variant summary: GCK c.667G>A (p.Gly223Ser) results in a non-conservative amino acid change located in the Hexokinase, C-terminal domain (IPR022673) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251410 control chromosomes (gnomAD). c.667G>A has been reported in the literature in multiple individuals affected with Maturity-onset diabetes of the young (Valentnov_2012, Garcia-Herrero_2012, Delvecchio_2014). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function and variant effect results in <10% of normal activity (Garcia-Herrero_2012). The following publications have been ascertained in the context of this evaluation (PMID: 11508276, 16965331, 17573900, 25414397, 22291974, 22493702). Six submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

AlphaMissense

Pathogenic

0.92

BayesDel_addAF

Pathogenic

0.56

BayesDel_noAF

Pathogenic

0.57

CADD

Pathogenic

DANN

Pathogenic

1.0

DEOGEN2

Pathogenic

0.92

.;D;.;.;.

Eigen

Pathogenic

1.0

Eigen_PC

Pathogenic

0.99

FATHMM_MKL

Uncertain

0.96

LIST_S2

Pathogenic

0.99

D;D;.;D;D

M_CAP

Pathogenic

0.41

MetaRNN

Pathogenic

0.99

D;D;D;D;D

MetaSVM

Pathogenic

1.0

MutationAssessor

Pathogenic

3.2

.;M;.;.;.

PrimateAI

Uncertain

0.78

PROVEAN

Pathogenic

-5.9

.;D;D;D;D

REVEL

Pathogenic

0.94

Sift

Pathogenic

0.0

.;D;D;D;D

Sift4G

Pathogenic

0.0

D;D;D;D;D

Polyphen

1.0

D;D;D;D;.

Vest4

0.94

MutPred

0.97

.;Gain of catalytic residue at G223 (P = 0.1571);.;.;.;

MVP

0.97

MPC

2.2

ClinPred

1.0

GERP RS

6.2

Varity_R

0.95

gMVP

1.0

Splicing

Name

Calibrated prediction

Score

Prediction

SpliceAI score (max)

0.50

Details are displayed if max score is > 0.2

DS_DG_spliceai

0.50

Position offset: 4

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Variant summary

Frequency

Consequence

Scores

Clinical Significance

Conservation

ACMG classification

Transcripts

RefSeq

Ensembl

Frequencies

ClinVar

Submissions by phenotype

Computational scores

Splicing

Publications

LitVar

Other links and lift over